Albumin: Indications in chronic liver disease. Issue 5 (June 2020)

• Record Type: Journal Article
• Authors: Tufoni, Manuel; Zaccherini, Giacomo; Caraceni, Paolo; Bernardi, Mauro
• Is Part Of: United European Gastroenterology journal. Volume 8:Issue 5(2020)
• Page Start: 528
• Page End: 535
• Publication Date: 2020-06
• Subjects: Liver cirrhosis -- ascites -- paracentesis -- human albumin -- acute kidney injury -- spontaneous bacterial peritonitis -- hepatorenal syndrome; Gastroenterology -- Periodicals; Periodicals; 616.33005
• DOI: 10.1177/2050640620910339
• Languages: English
• ISSNs: 2050-6406

Abstract

Albumin is currently employed as a plasma expander to prevent and treat specific complications of cirrhosis with ascites, such as the prevention of paracentesis-induced circulatory dysfunction and renal dysfunction induced by spontaneous bacterial peritonitis, as well as the diagnosis and treatment of acute kidney injury and hepatorenal syndrome. Recently, evidence has shown that long-term albumin administration in patients with decompensated cirrhosis reduces mortality and incidence of complications, eases the management of ascites, is cost effective, and has a good safety profile.